Clinical Applications of Mifepristone (RU486) and Other Antiprogestins: Assessing the Science and Recommending a Research Agenda

Mifepristone (RU486), the first clinically available antiprogestin, has generated great interest since its discovery in the early 1980s. Today, it is recognized that mifepristone, along with other antiprogestins, has a potentially significant therapeutic role in human health and disease, with likely...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Institute of Medicine, Committee on Antiprogestins: Assessing the Science
Format: Buch
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Institute of Medicine
Committee on Antiprogestins: Assessing the Science
description Mifepristone (RU486), the first clinically available antiprogestin, has generated great interest since its discovery in the early 1980s. Today, it is recognized that mifepristone, along with other antiprogestins, has a potentially significant therapeutic role in human health and disease, with likely applicability to a variety of pregnancy-related conditions (e.g., management of labor) and to contraception, endometriosis, and cancer, among others. But because mifepristone has been studied and used most widely as a means of nonsurgical abortion, political issues have thus far limited research on the drug and prevented its introduction into the U.S. market. This book provides an unbiased evaluation of current knowledge about both the fundamental nature of antiprogestins as well as their possible use in treating numerous diseases and conditions, and it contains recommendations for future research.
doi_str_mv 10.17226/2203
format Book
fullrecord <record><control><sourceid>nas</sourceid><recordid>TN_cdi_nas_primary_2203</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2203</sourcerecordid><originalsourceid>FETCH-nas_primary_22033</originalsourceid><addsrcrecordid>eNp1jr0KwjAAhCMi-JfZNaMOapqkTTOWoriIIDqXoKlGYhKSLL69Lbh6y93HwXEAwAxvMk5IsSUE0wGAgpeYYpGLkuZsCKY9YCaYwGMAY3zhThmhjPMJ2NdGW32TBlXemy4k7WxErkVH3SofdEzOKrQ8X1lZrJC0d3RKTxVQZZP2wT1UTNrGORi10kQFfz4Di_3uUh_WVsamW3nL8Gn6e_R_8wUP5jgY</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>book</recordtype></control><display><type>book</type><title>Clinical Applications of Mifepristone (RU486) and Other Antiprogestins: Assessing the Science and Recommending a Research Agenda</title><source>NCBI Bookshelf</source><creator>Institute of Medicine ; Committee on Antiprogestins: Assessing the Science</creator><contributor>Leslie Z. Benet ; Laneta Dorflinger ; Sarah S. Brown ; Molla S. Donaldson</contributor><creatorcontrib>Institute of Medicine ; Committee on Antiprogestins: Assessing the Science ; Leslie Z. Benet ; Laneta Dorflinger ; Sarah S. Brown ; Molla S. Donaldson</creatorcontrib><description>Mifepristone (RU486), the first clinically available antiprogestin, has generated great interest since its discovery in the early 1980s. Today, it is recognized that mifepristone, along with other antiprogestins, has a potentially significant therapeutic role in human health and disease, with likely applicability to a variety of pregnancy-related conditions (e.g., management of labor) and to contraception, endometriosis, and cancer, among others. But because mifepristone has been studied and used most widely as a means of nonsurgical abortion, political issues have thus far limited research on the drug and prevented its introduction into the U.S. market. This book provides an unbiased evaluation of current knowledge about both the fundamental nature of antiprogestins as well as their possible use in treating numerous diseases and conditions, and it contains recommendations for future research.</description><identifier>ISBN: 0309049490</identifier><identifier>ISBN: 9780309049498</identifier><identifier>EISBN: 9780309598354</identifier><identifier>EISBN: 0309598354</identifier><identifier>DOI: 10.17226/2203</identifier><language>eng</language><publisher>National Academies Press</publisher><creationdate>2017</creationdate><tpages>304</tpages><format>304</format><rights>1993</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>306,776,780,782,27902</link.rule.ids></links><search><contributor>Leslie Z. Benet</contributor><contributor>Laneta Dorflinger</contributor><contributor>Sarah S. Brown</contributor><contributor>Molla S. Donaldson</contributor><creatorcontrib>Institute of Medicine</creatorcontrib><creatorcontrib>Committee on Antiprogestins: Assessing the Science</creatorcontrib><title>Clinical Applications of Mifepristone (RU486) and Other Antiprogestins: Assessing the Science and Recommending a Research Agenda</title><description>Mifepristone (RU486), the first clinically available antiprogestin, has generated great interest since its discovery in the early 1980s. Today, it is recognized that mifepristone, along with other antiprogestins, has a potentially significant therapeutic role in human health and disease, with likely applicability to a variety of pregnancy-related conditions (e.g., management of labor) and to contraception, endometriosis, and cancer, among others. But because mifepristone has been studied and used most widely as a means of nonsurgical abortion, political issues have thus far limited research on the drug and prevented its introduction into the U.S. market. This book provides an unbiased evaluation of current knowledge about both the fundamental nature of antiprogestins as well as their possible use in treating numerous diseases and conditions, and it contains recommendations for future research.</description><isbn>0309049490</isbn><isbn>9780309049498</isbn><isbn>9780309598354</isbn><isbn>0309598354</isbn><fulltext>true</fulltext><rsrctype>book</rsrctype><creationdate>2017</creationdate><recordtype>book</recordtype><recordid>eNp1jr0KwjAAhCMi-JfZNaMOapqkTTOWoriIIDqXoKlGYhKSLL69Lbh6y93HwXEAwAxvMk5IsSUE0wGAgpeYYpGLkuZsCKY9YCaYwGMAY3zhThmhjPMJ2NdGW32TBlXemy4k7WxErkVH3SofdEzOKrQ8X1lZrJC0d3RKTxVQZZP2wT1UTNrGORi10kQFfz4Di_3uUh_WVsamW3nL8Gn6e_R_8wUP5jgY</recordid><startdate>20170317</startdate><enddate>20170317</enddate><creator>Institute of Medicine</creator><creator>Committee on Antiprogestins: Assessing the Science</creator><general>National Academies Press</general><scope>N87</scope></search><sort><creationdate>20170317</creationdate><title>Clinical Applications of Mifepristone (RU486) and Other Antiprogestins</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-nas_primary_22033</frbrgroupid><rsrctype>books</rsrctype><prefilter>books</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Institute of Medicine</creatorcontrib><creatorcontrib>Committee on Antiprogestins: Assessing the Science</creatorcontrib><collection>National Academies Press Free eBooks</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leslie Z. Benet</au><au>Laneta Dorflinger</au><au>Sarah S. Brown</au><au>Molla S. Donaldson</au><aucorp>Institute of Medicine</aucorp><aucorp>Committee on Antiprogestins: Assessing the Science</aucorp><format>book</format><genre>book</genre><ristype>BOOK</ristype><btitle>Clinical Applications of Mifepristone (RU486) and Other Antiprogestins: Assessing the Science and Recommending a Research Agenda</btitle><date>2017-03-17</date><risdate>2017</risdate><isbn>0309049490</isbn><isbn>9780309049498</isbn><eisbn>9780309598354</eisbn><eisbn>0309598354</eisbn><abstract>Mifepristone (RU486), the first clinically available antiprogestin, has generated great interest since its discovery in the early 1980s. Today, it is recognized that mifepristone, along with other antiprogestins, has a potentially significant therapeutic role in human health and disease, with likely applicability to a variety of pregnancy-related conditions (e.g., management of labor) and to contraception, endometriosis, and cancer, among others. But because mifepristone has been studied and used most widely as a means of nonsurgical abortion, political issues have thus far limited research on the drug and prevented its introduction into the U.S. market. This book provides an unbiased evaluation of current knowledge about both the fundamental nature of antiprogestins as well as their possible use in treating numerous diseases and conditions, and it contains recommendations for future research.</abstract><pub>National Academies Press</pub><doi>10.17226/2203</doi><tpages>304</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISBN: 0309049490
ispartof
issn
language eng
recordid cdi_nas_primary_2203
source NCBI Bookshelf
title Clinical Applications of Mifepristone (RU486) and Other Antiprogestins: Assessing the Science and Recommending a Research Agenda
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T19%3A42%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-nas&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=book&rft.btitle=Clinical%20Applications%20of%20Mifepristone%20(RU486)%20and%20Other%20Antiprogestins:%20Assessing%20the%20Science%20and%20Recommending%20a%20Research%20Agenda&rft.au=Leslie%20Z.%20Benet&rft.aucorp=Institute%20of%20Medicine&rft.date=2017-03-17&rft.isbn=0309049490&rft.isbn_list=9780309049498&rft_id=info:doi/10.17226/2203&rft_dat=%3Cnas%3E2203%3C/nas%3E%3Curl%3E%3C/url%3E&rft.eisbn=9780309598354&rft.eisbn_list=0309598354&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true